Cargando…
Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19
The world is currently experiencing the worst health pandemic since the Spanish flu in 1918—the COVID-19 pandemic—caused by the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic is the world’s third wake-up call this century. In 2003 and 2012, the world experien...
Autores principales: | McGowan, Eileen M, Haddadi, Nahal, Nassif, Najah T., Lin, Yiguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583882/ https://www.ncbi.nlm.nih.gov/pubmed/33003377 http://dx.doi.org/10.3390/ijms21197189 |
Ejemplares similares
-
Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget
por: Hatoum, Diana, et al.
Publicado: (2017) -
PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
por: Haddadi, Nahal, et al.
Publicado: (2018) -
Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
por: Bu, Yanhong, et al.
Publicado: (2021) -
“Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer
por: Haddadi, Nahal, et al.
Publicado: (2017) -
Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR/SphK1 crosstalk
por: Schiefler, Carlotta, et al.
Publicado: (2014)